You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

261 Results
Document
May 2020
Document
May 2020
Document
May 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
riTUXimab,
CISplatin,
cytarabine,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2020
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
dacarbazine,
DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Exceptional Access Program
    pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
isatuximab,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selinexor (Unfunded),
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
durvalumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Drug
Other Name(s): Nubeqa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024

Pages